Search Within

Carolyn Wasserheit-Lieblich

Formats
  1. Journal Article (9)
  2. Meeting Abstract (6)
  3. Conference Paper (2)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (13)
  2. Department of Medicine (13)
  3. Solid Tumor Oncology Division (13)
  4. Breast Medicine Service (12)
  5. Survivorship Research (10)
  6. Biostatistics Service (8)

More Groups

People
  1. Larry Norton (10)
  2. Clifford Hudis (9)
  3. Pamela Drullinsky (8)
  4. Steven Sugarman (8)
  5. Diana Lake (7)
  6. Gabriella D'Andrea-Carlino (7)

More People

Years
  1. 2015 (1)
  2. 2014 (2)
  3. 2011 (1)
  4. 2010 (1)
  5. 2009 (1)
  6. 2008 (1)

More Years

Publications
  1. Breast Cancer Research and Treatment (3)
  2. Cancer Research (2)
  3. Clinical Breast Cancer (2)
  4. Journal of Clinical Oncology (2)
  5. Women's Oncology Review (2)
  6. Annals of the New York Academy of Sciences (1)

More Publications

Publishers
  1. Elsevier Inc. (3)
  2. Springer (3)
  3. American Association for Cancer Research (2)
  4. American Society of Clinical Oncology (2)
  5. Taylor & Francis Group (2)
  6. American Society of Hematology (1)

More Publishers

Results (17)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result
    Meeting Abstract

    Smyth, L. M.; Iyengar, N. M.; Chandarlapaty, S.; Sugarman, S.; Comen, E. A.; Drullinsky, P.; Sklarin, N. T.; Traina, T. A.; Troso-Sandoval, T. A.; Patil, S.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Greater total dose and duration of treatment with bortezomib are associated with higher incidence of chalazion and other ocular side effects
    Meeting Abstract

    Ganesh, K.; Batlevi, C.; Zhang, Z. G.; Hassoun, H.; Lendvai, N.; Landau, H.; Moskowitz, C. H.; Caron, P.; Motzer, R.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with Metastatic breast cancer
    Journal Article

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Robson, M.; Goldfarb, S.; Drullinsky, P.; Sugarman, S.; Wasserheit Leiblich, C.; Fasano, J.; more...
    Clinical Breast Cancer (2014)

    Fulltext@MSK | Save
  • A phase II trial of ganetespib: Efficacy and safety in patients (pts) with metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Drullinsky, P.; Sugarman, S.; Wasserheit-Leiblich, C.; Moynahan, M. E.; D'Andrea, G.; Haque, S.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer
    Journal Article

    Drullinsky, P.; Sugarman, S. M.; Fornier, M. N.; D'Andrea, G.; Gilewski, T.; Lake, D.; Traina, T.; Wasserheit-Lieblich, C.; Sklarin, N.; Atieh-Graham, D.; more...
    Clinical Breast Cancer (2010)

    Fulltext@MSK | Save
  • A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma
    Journal Article

    Sugarman, S.; Wasserheit, C.; Hodgman, E.; Coglianese, M.; D'alessandro, A.; Fornier, M.; Troso-Sandoval, T.; D'Andrea, G.; Drullinsky, P.; Lake, D.; more...
    Breast Cancer Research and Treatment (2009)

    Fulltext@MSK | Save
  • The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Journal Article

    Dang, C.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Dickler, M.; Currie, V.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • A pilot study of growth factor (GF) omission during paclitaxel (T) for women with early breast carcinoma (BC)
    Meeting Abstract

    Sugarman, S. M.; Wasserheit, C.; Hodgman, E.; Coglianese, M. E.; D'alessandro, A.; Fornier, M.; Troso-Sandoval, T.; D'Andrea, G.; Drullinsky, P.; Lake, D.; more...
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save
  • Mature cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C.; Smith, K.; Fornier, M.; Sugarman, S.; Troso, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; George, R.; more...
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save
  • [Commentary on] Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial
    Journal Article

    Mills, N. E.; Wasserheit, C.
    Women's Oncology Review (2002)

    Fulltext@MSK | Save